CTRI/2021/10/037519已完成2 期
A PHARMACEUTICO-CLINICAL STUDY OF ARAGVADHADYAM TAILAM AND DHATRI KHADIR KWATH ON SHVITRA WITH SPECIAL REFRENCE TO VITILIGO
GOVERMENT AYURVEDA COLLEGE AND HOSPITAL PATNA1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年10月25日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Improvement in signs and symptoms of Shvitra.
研究概览
简要总结
Shvitra is considered as one of the varieties of Kushtha, that can be correlated with Vitiligo based on the similarities of signs and symptoms. It is caused due to the vitiation of tridosha and dhathus like rasa, rakta, mamsa and meda. Dhatri khadir kwath and Aragvadhadyam tailam yoga are formulations described in chapter Kushtha Chikitsa of Chakradutta for Shvitra, are selected for the present study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 21.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patient willing for trial, having signs and symptoms (classical along with some modern parameters).
排除标准
- •Patients suffering from AIDS, Cancer, TB, Cardiac complications, patients of Sprue disease, Malabsorption, HB% below 7gm/dl, pregnant women.
- •Vitiligo patches that rapidly spread and become associated with redness, blister formation, itching during therapy or as such.
结局指标
主要结局
Improvement in signs and symptoms of Shvitra.
时间窗: 90 days
次要结局
- Improvement in signs and symptoms of Shvitra.(Evaluation will be done after 90 days)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Etiopathology study of Shvitra(Vitiligo) and Therapeutic uses of Dhatri Khadiradi YogCTRI/2021/07/035085Madan mohan malviya govt ayurved college
尚未招募
不适用
Efficacy of therapeutic emesis with Ikshvaku drug in PsoriasisCTRI/2025/06/089193SGT University60
已完成
不适用
Effect of chitrak rasayan and bakuchyadi lepa on leucodermaCTRI/2021/11/038011Government Ayurvedic College Patna Bihar30
已完成
不适用
Effect of chitrak rasayan and bakuchyadi lepa on leucodermaCTRI/2021/11/038011Government Ayurvedic College Patna Bihar30
已完成
2 期
A clinical trial to compare the effects of two methods of obtaining hair stem cells for treating vitiligoCTRI/2016/08/00713321